share_log

摩根士丹利:维持药明康德「增持」评级及目标价177港元

Morgan Stanley: maintain Wuxi Apptec's "overweight" rating and target price of HK $177,

Moomoo 24/7 ·  Sep 16, 2022 03:34
Morgan Stanley said in a report that US President Joe Biden signed a new executive order that will guide more money to invest in the US biological manufacturing industry. The bank believes that the financial impact of the above US executive order on Wuxi Apptec is limited. The company's short-and medium-term growth trajectory is expected to remain unchanged. This is thanks to a large number of new drug pipelines (accounting for 16% of new drugs in the global clinical phase) within the Group's CRDMO (contract Research, Development and production) model. Wuxi Apptec is building a commissioned production service (CMO) facility for finished drugs in the US, which should be able to adapt to any long-term shift in US biomanufacturing outsourcing strategy. Morgan Stanley said it maintained its "overweight" rating on Wuxi Apptec and its target price of HK $177m.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment